Neusoft and Shenyang Pharmaceutical University Sign Agreement to Build Digital Intelligence Pharmaceutical
On September 11, 2026, Neusoft Group and Shenyang Pharmaceutical University formally signed a specific cooperation agreement to jointly build the Shenyang Pharmaceutical University-Neusoft Group Digital Intelligence Pharmaceutical Research Institute.
The institute will focus on five areas: AI-assisted new drug development, clinical pharmacy and precision medication, digital pharmacy and real-world research, smart medical data and clinical decision support, and pharmaceutical big data governance and standardization.
The two parties will also establish long-term cooperation mechanisms, including joint scientific research, joint postgraduate training, and two-way talent secondment.
Why this event matters
The event has a measured impact on 3 industrys. The strongest current signal is positive for Artificial Intelligence, with intensity 40/100 and 60% confidence over a medium term horizon.
Artificial Intelligence
- Direction
- positive
- Intensity
- 40
- Confidence
- 60%
- Horizon
- Medium term
Pharmaceutical R&D Services
- Direction
- positive
- Intensity
- 35
- Confidence
- 55%
- Horizon
- Medium term
Enterprise Software
- Direction
- positive
- Intensity
- 30
- Confidence
- 50%
- Horizon
- Medium term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.